Zacks Investment Research downgraded shares of Pharming Group (NASDAQ:PHGUF) from a hold rating to a sell rating in a report published on Tuesday morning.
According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “
Shares of Pharming Group (NASDAQ:PHGUF) opened at 0.53 on Tuesday. Pharming Group has a 1-year low of $0.17 and a 1-year high of $0.58. The stock’s market cap is $267.98 million.
COPYRIGHT VIOLATION NOTICE: “Pharming Group (PHGUF) Lowered to Sell at Zacks Investment Research” was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/2888493/pharming-group-phguf-lowered-to-sell-at-zacks-investment-research.html.
About Pharming Group
Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.